# A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer

> **NCT01036113** · PHASE2 · TERMINATED · sponsor: **Enzon Pharmaceuticals, Inc.** · enrollment: 160 (estimated)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** EZN-2208

## Key facts

- **NCT ID:** NCT01036113
- **Lead sponsor:** Enzon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2012-02
- **Final completion:** 2012-12
- **Target enrollment:** 160 (ESTIMATED)
- **Why stopped:** Program suspended and divested
- **Last updated:** 2022-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01036113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01036113, "A Phase 2 Study of EZN-2208 in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01036113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*